News

Home/News/

Dimebon Fails Again; End of the Road in Alzheimer’s

January 18, 2012 — Topline results of a phase 3 trial of dimebon, also called latrepirdine, on top of ongoing treatment with donepezil has shown no benefit in patients with mild to moderate Alzheimer’s disease (AD). The companies developing dimebon in this indication, Medivation Inc and Pfizer Inc, issued a joint statement noting that results [...]

Protein-Based Biomarkers in Blood Serum Could Classify Individuals With Alzheimer’s Disease

9.13.2010 Protein-Based Biomarkers in Blood Serum Could Classify Individuals With Alzheimer's Disease Archives of Neurology, JAMA An initial analysis suggests that biomarkers in blood serum can be combined with clinical information to accurately classify patients with Alzheimer’s disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

UT Health Science Center in San Antonio Recruiting 500 Hispanics age 59 or older

4.01.2010 UT Medicine San Antonio Physicians at Forefront of Alzheimer's Research The Mission Psychiatrist Donald R. Royall, M.D., and neurologist Gustavo C. Roman, M.D., are recruiting 500 Hispanics age 59 or older for a longitudinal study that will attempt to determine the prevalence of Alzheimer's in the Hispanic population and pinpoint risk factors.

Go to Top